— Meta-analysis of 14 RCTs revealed substantial decreases in infection, hospitalization
by Elizabeth Short, Staff Writer, MedPage Today
February 17, 2023
Prophylactic usage of 3 monoclonal antibodies was connected with considerable decreases in breathing syncytial infection (RSV)-associated infections and hospitalizations in kids under 5, an organized evaluation and meta-analysis revealed.
Throughout 14 randomized regulated trials including over 18,000 high-risk kids, moderate- to high-certainty proof revealed that nirsevimab, palivizumab, and motavizumab were related to considerable decreases in RSV-related infections and hospitalizations per 1,000 individuals compared to placebo, reported Long Ge, PhD, of Lanzhou University in Lanzhou City, China, and associates:
- Nirsevimab: -123 (95% CI -138 to -100) and -54 (95% CI -64 to -38)
- Palivizumab: -108 (95% CI -127 to -82) and -39 (95% CI -48 to -28)
- Motavizumab: -136 (95% CI -146 to -125) and -48 (95% CI -58 to -33)
Moderate-certainty proof revealed that extensive care system admissions per 1,000 individuals were substantially lower with motavizumab (-8, 95% CI -9 to -4) and palivizumab (-5, 95% CI -7 to 0), as was extra oxygen usage per 1,000 individuals (-59 [95% CI -63 to -54] and -55 [95% CI -61 to -41]respectively), while nirsevimab was connected with substantially minimized extra oxygen usage per 1,000 individuals (-59, 95% CI -65 to -40), they kept in mind in JAMA Network Open
No substantial distinctions were discovered in all-cause death or drug-related unfavorable occasions.
While 4 monoclonal antibodies were consisted of in the meta-analysis, suptavumab revealed no considerable advantages.
“The World Health Organization released files in 2021 that currently motivated the advancement of preventive int